Kornimate/medical-research-clean huggingface dataset:
sensorimotor training and constraint induced movement therapy on upper extremity function in children with hemiplegic cp

Conditions: Hemiplegic Cerebral Palsy

Summary: the aim of the work was to find out the effects of sensorimotor training and constraint induced movement therapy on upper extremity function in children with hemiplegic cerebral palsy.

the significance of this study is that there was paucity of literature in finding the comparative effects of sensorimotor training and constraint induced movement therapy on upper extremity function in children with hemiplegic cerebral palsy. the aim is to find out the effects of sensorimotor training on motor functioning of the upper extremity in comparison of constraint induced movement therapy.

Eligibility criteria:
inclusion criteria: * subjects who were fully oriented * children diagnosed with hemiplegic cerebral palsy * no history of intramuscular botulinum injections past one year exclusion criteria: * children with epilepsy * gross deformity of upper limb * children with contractures

Keywords: sensorimotor training motor function constraint induced movement therapy
ocular blood flow imaging for glaucoma assessment

Conditions: Glaucoma

Summary: the goal of this clinical trial is to investigate the use of an fda-cleared retinal blood flow imaging instrument called the xycam ri and xycam fc (vasoptic medical, inc., columbia, md) in glaucoma management. the main question it aims to answer are: * can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls? * can the investigators validate that the xycam fc simultaneously captures both stereo fundus photography and ocular blood flow monitoring? participants will be * measured for their blood pressure, heart rate, height, and weight * dilated with tropicamide * imaged using the xycam ri, fundus photography, optical coherence tomography, and standard automated perimetry * imaged using the xycam ri while inhaling 100% oxygen through a mask

the investigators will capture images of the participant's retina using the xycam ri or xycam fc ("test data") and by color fundus photography, optical coherence tomography (oct), and standard automated perimetry (sap) - the "standard clinical data". the investigators will perform five tests. the first two tests will be conducted using the xycam ri or xycam fc to obtain "test data". the final two tests will be conducted using routine clinical instruments to obtain "standard clinical data". the investigators will administer eye drops (tropicamide) to dilate the participant's pupils prior to the first test. tropicamide is a chemical that causes pupil dilation and is commonly used by doctors to examine the participant's eyes. the entire set of test data sessions should last less than eighty (80) minutes with an additional 60 minutes for carrying out the necessary procedures and imaging using the standard clinical data.

Eligibility criteria:
inclusion criteria: * age 18 and older with binocular vision * able to provide informed consent * patient is a healthy control or is recommended for glaucoma assessment or diagnosed with moderate to severe glaucoma in at least one eye as determined by hodapp anderson criteria exclusion criteria: * the subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar) * the subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (alt or slt), or yag capsulotomy * the subject has prior ocular disease other than glaucoma * the subject has anatomically narrow angles or a prior adverse reaction to administration of tropicamide or fluorescein dye * the subject has more than 15 diopters of refractive error * the subject is a female who is pregnant or nursing * the subject has diabetes mellitus

Keywords: glaucoma xycam blood flow imaging ophthalmology retinal blood flow eye disease
characterization of the microvascular dysfunction in covid-19 ards

Conditions: ARDS, Human; COVID-19 Acute Respiratory Distress Syndrome

Summary: the primary endpoint of this research is to establish that the alveolar dead space is significantly higher in patients with covid-19 ards, compared to patients with non-covid-19 ards. secondarily, the investigators want to establish the prognostic value of the alveolar-dead space (measured iteratively) in patients with covid-19 and non-covid-19 ards, to establish the respective influences of the biological parameters of endothelial damage, of the biological parameters of coagulopathy, of the parameters set on the artificial ventilator on the value of the alveolar dead space; in ards patients with covid-19 and non-covid-19 ards, to establish the prognostic value of the laboratory parameters of endothelial damage and coagulopathy in patients with covid-19 and non-covid-19 ards.

endothelial damage and coagulation activation at the lung microvascular level may play an important role in the physiopathology of the covid-19 ards. the project aims to prospectively investigate both bedside pulmonary physiological markers and biological markers of coagulopathy and endothelial dysfunction in covid-19 and non-covid-19 ards patients.

Eligibility criteria:
inclusion criteria: * age\> 18 years old * invasive mechanical ventilation in place for less than 48 hours * severe or moderate ards (defined according to the berlin classification) * virological confirmation by pcr of sars-cov-2 infection (ards covid-19) * lack of virological confirmation by pcr of sars-cov-2 infection (ards not linked to covid-19) * patient information exclusion criteria: * massive pulmonary embolism * chronic respiratory failure under long-term oxygen therapy * dying patient

Keywords: pulmonary biological markers alveolar dead-space circulating endothelial cells
sodium fluoride pet/ct for the evaluation of skeletal cancer

Conditions: Bone Cancer

Summary: this clinical trial studies fluorine f-18 sodium fluoride positron emission tomography (pet)/computed tomography (ct) in diagnosing bone tumors in patients with cancer. diagnostic procedures, such as fluorine f-18 sodium fluoride pet/ct, may help find and diagnose bone cancer

the objective of the study is to use 18f sodium fluoride (fluorine f-18 sodium fluoride) pet/ct scanning to detect and characterize lesions in patients who have suspected skeletal malignancy. we hypothesize that scanning with 18f-naf (fluorine f-18 sodium fluoride) is more sensitive for skeletal abnormalities and may better characterize lesions than conventional imaging.

Eligibility criteria:
inclusion criteria: * patients referred for evaluation of suspected skeletal cancer * patients must understand and voluntarily sign an informed consent form after the contents have been fully explained to them exclusion criteria: * patients who cannot complete a pet/ct scan * pregnant women * healthy volunteers
evaluation of the role of local steroid injection in treatment of idiopathic spasmodic flat foot in adolescent patients

Conditions: Flatfoot

Summary: * population: adolescent patients aged from 10 to 16 years * interventions: 1. examination under general anaesthesia if the deformity corrected spontaneously 2. local injection of steroid in sinus tarsi 3. cast in varus for 6 weeks * outcomes: primary outcome : evaluate the clinical and functional outcomes according aofas. * time: follow up within one and half month, 3 months, 6 months, one year.

• does local steroid injection have a role in treatment of spasmodic flat foot in adolescent patients? one of the most common foot complaints in the juvenile and adolescent age group is the "flatfoot" deformity. (1) clinical evaluation of flatfeet primarily focuses on differentiation between the two main types: flexible and rigid. (2) the flexible type is a common diagnosis and is one which is usually not problematic and rarely needs treatment. (3) rigid flatfoot deformity is less common (occurring one-third as often as the flexible type) but often is symptomatic and requires treatment. (4) spasmodic valgus foot is usually associated with resistant pain and deformity. it shows controversy regarding its incidence, etiology, and treatment. (5) spasmodic flatfoot is a rare condition characterized by a rigid and usually painful valgus deformity in the hind foot with peroneal muscles spasms (6,7) it is often caused by inter-tarsal bars or bone anomalies that restrict tarsal joint motion . (8) our study aims to evaluate the functional and clinical outcome after local long-acting steroid injection in the sinus tarsi followed by cast in adolescent patients with spasmodic flatfeet without coalition.

Eligibility criteria:
inclusion criteria: * age of the patients from 10 to 16 years * flat foot with peroneal muscle spasm exclusion criteria: * flatfoot uncorrected by manipulation under general anaesthesia * neuromuscular disorders * evidence of coalition in ct or mri
clinical use of andante smartstep system in gait rehabilitation

Conditions: Ankle Injuries; Femoral Neck Fractures

Summary: the purpose of this study is to evaluate the effectiveness of the biofeedback gait training device in improving load bearing over an operated limb, during post-operative gait training therapy. the effectiveness of the device will also be tested in self-training at home.

to evaluate the effectiveness of the biofeedback gait training device as a biofeedback training therapeutic tool in improving body-weight bearing over the affected lower limb, quality of gait, level of ambulation and physical independence during rehabilitation, in patients after orthopedic procedures during gait therapy training, and as a biofeedback device for self-training at home.

Eligibility criteria:
inclusion criteria: * rehabilitation after operation * patient is allowed full weight bearing * patient is motivated and able to communicate and understands orders * patient is able to walk 10 meters * patient filled out agreement and consent form exclusion criteria: * activity limitation due to medical disorder, medications, or emotional status. * pain markedly obstructs gait ability * documented peripheral neuropathy * functional limitation prior to the current condition * premorbid, ongoing major depression or psychosis * multiple/pathological fractures * serious early complications * terminally ill patients * pregnant women * participation in current or recent (within 60 days prior to surgery) clinical trial

Keywords: arthroplasty, replacement, hip arthroplasty, replacement, knee arthroscopy
epidemiology and prognostic of the acute heart failure

Conditions: Decompensated Chronic Heart Failure; Heart Failure NYHA Class III; Acute Pulmonary Edema; Cardiogenic Shock; Heart Failure NYHA Class IV

Summary: epical 2 (epidemiology and prognostic of the acute heart failure) is an epidemiological, observational, prospective and multicenter study. this study includes at first an exhaustive recording of the cases on a geographic area at east of france, then the recorded patients are followed up in a cohort at least 3 years. this study follows the experiences of the epical study led by our team. main objective: to describe the characteristics of the patients affected by acute heart failure and to identify prognostic factors, in particular related to care. more exactly : * to describe the sociodemographic, clinical, biological and therapeutic characteristics of the patients presenting an acute heart failure during hospitalisation and living at east of france ; * to study the short and medium-term morbi-mortality of these patients, and identify the main factors determining the prognosis for survival ; * to evaluate the prognostic impact of the intra and extra-hospital care ; * to identify the evolution of the care's practices of the decompensated heart failure since the epical study (15 years) and their influence on the prognosis of the disease. secondary objective: to constitute a biological collection of serum, plasma and urine of patients' sample presenting an acute heart failure.

criteria of inclusion: * patients hospitalized for acute heart failure or developing an acute heart failure during the hospitalisation in the intensive care, cardiology or geriatrics departments of the hospitals of northeast of france during one year * patients died in emergencies or during the transfer, with a diagnosis of acute heart failure. acute heart failure includes decompensation of chronic heart failure, advanced stage of the heart failure, acute oedema of the lung and cardiogenic shock. according to the data of registers, the incidence of the acute heart failure in approximately 2,5 cases per 1000 adults per year, the expected sample size amounts to 2500 eligible patients over 1 year. data collection: the doctors declare the acute heart failure of their departments. the technicians of clinical research collect the data concerning the sociodemographic, clinical, biological and therapeutic characteristics of the inclusive patients on arrival at the hospital, during the hospitalisation and at the exit. the biological takings are made for the patients having given their consent before the exit of the hospitalization. the patients are followed up during 3 years.

Eligibility criteria:
inclusion criteria : * patients hospitalized for acute heart failure or developing an acute heart failure during the hospitalisation in the intensive care, cardiology or geriatrics departments of the hospitals of northeast of france during one year * patients died in emergencies or during the transfer, with a diagnosis of acute heart failure.
regorafenib post-marketing surveillance in japan

Conditions: Gastrointestinal Stromal Tumors

Summary: the objective of this study is to assess safety and effectiveness of regorafenib using in real clinical practice

this study is a regulatory post-marketing surveillance in japan, and it is a local prospective and observational study of patients who have received regorafenib for gastrointestinal stromal tumors progressed after cancer chemotherapy. a total of 135 patients are to be enrolled and assessed in 6 months standard observational period. at 12 months and 24 months after the first administration of regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient.

Eligibility criteria:
inclusion criteria: * patients who are treated with regorafenib/ stivarga and meet the product label. exclusion criteria: * patients who are treated with regorafenib/ stivarga and don't meet the product label.

Keywords: regorafenib gastrointestinal stromal tumors
a cluster-rct to increase the uptake of larcs among adolescent females and young women in cameroon.

Conditions: Contraception Behavior; Contraceptive Usage; Contraceptive Method Switching; Contraception

Summary: the study investigators propose to test various supply-side approaches to increase the numbers of both sarcs (short-acting reversible contraceptives, i.e. the pill and injectable) and especially larcs (long-acting reversible contraceptives, i.e. the iud and implant) administered by health facilities to reproductive-age females in cameroon, particularly adolescents who may be unmarried and/or nulliparous. the study investigators will do this via interventions at primary health facilities, which include training of providers on family planning; the introduction of a tablet-based decision support tool for counseling women on family planning; and increased subsidies for larcs within the performance-based financing (pbf) system. this approach is expected to benefit the population directly by decreasing maternal mortality and undesired pregnancies and indirectly by reducing side effects that arise due to current one-size-fits-all fp (family planning) counseling; improving the health of children due to improved birth spacing; and increasing human capital accumulation among children and young (often school-age) potential mothers.


Eligibility criteria:
inclusion criteria: * facilities in the east region of cameroon providing family planning services under the performance-based financing (pbf) system. exclusion criteria: * facilities that have not administered any modern contraceptive methods in the past quarter

Keywords: adolescent sexual and reproductive health, maternal mortality, teen pregnancy, larcs
dexketoprofen dosage according to chronotherapy

Conditions: Tooth, Impacted; Trismus; Pain; Inflammatory Response

Summary: lower third molar extraction is one of the most common treatments in oral surgery practice. it is a treatment with inherent complications such as postoperative pain, swelling or trismus. in order to minimize disconfort after extraction, analgesic and anti-inflammatory medication is prescribed. recently, it is seen that circadian rhythm may play an important role on drugs metabolism, modulating its effect depending on the moment of administration. the aim of the study is to analyze if dosage modification of a non steroideal anti-inflammatory (dexketoprofen) affects on postoperative pain, swelling and open mouth limitation according the circadian clock

a randomized crossover split-mouth clinical trial will be performed. after third molar extractions, patients will be prescribed randomly in one side intake morning medication dosage while the contralateral side will be prescribed a night dosage. moreover, a blood sample will be obtained to analyze the inflammatory profile.

Eligibility criteria:
inclusion criteria: * bilateral impacted lower third molar exclusion criteria: * nsaid allergic * contraindication of surgery

Keywords: third dexketroprofen randomized
heart rate variability and inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: the goals of this study are to test the effectiveness of a virtually delivered, group-based coping skills treatment program incorporating heart rate variability biofeedback to target autonomic dysfunction in youth diagnosed with inflammatory bowel disease (ibd). the investigators will enroll participants with ibd in a biofeedback enhanced cognitive behaviorally based coping skills treatment. participants will be randomized to biofeedback enhanced treatment or wait-list control.

the goals of this study are to test the effectiveness of a virtually delivered, group-based coping skills treatment program incorporating heart rate variability biofeedback to target autonomic dysfunction in youth diagnosed with inflammatory bowel disease (ibd). patients are youth ages 13-18 recruited through ibd clinics at children's healthcare of atlanta. enrollment will include up to 128 children with at least 1 parent. this study will last 7-months and will have 4 in person study visits, lasting about 1 hour each, as well as 6 virtual treatment sessions lasting about 45 minutes each. study procedures will include surveys, chart/record review, blood sampling, and non-invasive assessments of psychophysiological functioning. stool samples will be collected and stored. informed consent and assent will be obtained in-person or remote signed.

Eligibility criteria:
inclusion criteria: * diagnosis with biopsy-confirmed ibd for at least 4 months, * ages 13 through 18 years inclusive, * speak english, * enrolling with at least 1 parent/guardian who is willing to participate by completing surveys, * positive depression or anxiety screens using the phq-4, - access to home internet to participate in virtual intervention, * youth and parent agree to the conditions of study participation, including randomization, participation in intervention, and follow-up assessments, * youth is medically approved to engage in normal daily activities (e.g., attend school, extracurricular activities) exclusion criteria: * previous diagnosis of developmental disabilities that require full-time special education or that impair the ability to respond to treatment, * diagnosis with any other chronic disease (e.g., diabetes, epilepsy, etc.), * diagnosis of abnormal thyroid function, * treatment with any drug with known autonomic cardiovascular influences including beta-blockers, central sympatholytic agents, or antidepressants.

Keywords: cognitive behavioral therapy heart rate variability
a study to investigate the influence of pth-lowering by etelcalcetide (parsabiv®) on the calcification propensity of serum in dialysis patients

Conditions: End Stage Renal Disease

Summary: this is a single-center, prospective, dose-escalation, pilot study in 15 end-stage renal disease patients on chronic hemodialysis with secondary hyperparathyroidism.

fifteen prevalent and stable hemodialysis patients with secondary hyperparathyroidism eligible for treatment with calcium receptor sensitizers according to current kdigo will be included. study phases will begin and end on the day of the first hemodialysis session of the week. the run-in phase will last 4 weeks. no calcimimetics will be prescribed during the run-in phase. the treatment phase starts with a dose of etelcalcetide is 2.5mg thrice weekly. etelcalcetide dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly. the wash-out phase starts after completion of the 15mg thrice-weekly phase or in case a pre-specified safety endpoint is reached, etelcalcetide will be discontinued and patients will be followed for additional 8 weeks to study any potential reversibility of pth lowering on t50 results. for the individual patient, the study duration will be 9 months

Eligibility criteria:
inclusion criteria: * prevalent patients (≥ 3 months on dialysis) treated with thrice weekly hemodialysis (hd) or hemodiafiltration (hdf) * secondary hyperparathyroidism defined as pth levels \> 9x uln according to current kdigo guidelines if therapy-naïve, or patients already treated with calcium receptor sensitizers with pth \> 2x uln * albumin corrected calcium ≥ 2,08 mmol/l * calcium concentrations of dialysate stable for at least 2 weeks prior to screening exclusion criteria: * currently receiving treatment in another investigational device or drug study or participation in non-interventional studies * current treatment with etelcalcetide (parsabiv©) or treatment with etelcalcetide within 3 months prior to study inclusion * patient has known sensitivity to any of the products or components of parsabiv© * patient has received a parathyroidectomy * parathyroidectomy planned or expected during the study period * elective kidney transplant scheduled during the study period * therapy with bisphosphonates within the past 12 months * therapy with denosumab within the past 6 months * antacids containing aluminum, calcium, magnesium or bicarbonate * patient has a history of symptomatic ventricular arrhythmias or torsades de pointes * patient has a history of myocardial infarction, coronary angioplasty, or coronary arterial bypass grafting within the past 6 months prior to screening. * pregnant or nursing (lactating) women
"the effects of oxytocin on patients with borderline personality disorder"

Conditions: Effects of Oxytocin on Borderline Personality Disorder; Borderline Personality Disorder

Summary: rct. two substudies (clinical and experimental). main objective of the trial is to examine if oxytocin, compared to placebo shows any additional effect on the therapy achievements (outcome) of patients with borderline personality disorder, who receive an in-patient standard psychotherapy (dialectical-behavioral-therapy, marsha linehan (2006)). secondary objectives : investigate if oxytocin compared to placebo enhances social trust and emotion recognition in patients with borderline personality disorder. comparison of the effects of oxytocin on patients with bpd and major depression.


Eligibility criteria:
inclusion criteria: * gender: both, male and female * minimum age: 18 years * maximum age: 50 years * borderline personality disorder or major depression (clinical control group) * mini mental status test \> 27 (capacity to consent) exclusion criteria: * chronic or acute somatic health problems * schizophrenia * bipolar affective disorder * pregnancy * breast feeding * neurological disorder * allergy to antidegradants

Keywords: oxytocin bpd borderline